Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology - PubMed (original) (raw)

Practice Guideline

. 2024 Sep;22(7):483-506.

doi: 10.6004/jnccn.2024.0046.

Bjorn Holmstrom 2, Dana Angelini 3, Aneel Ashrani 4, Tyler Buckner 5, Robert Diep 6, Kleber Yotsumoto Fertrin 7, Annemarie E Fogerty 8, Nicolas Gallastegui Crestani 9, Radhika Gangaraju 10, Cristhiam Rojas-Hernandez 11, Samuel Z Goldhaber 12, Ibrahim Ibrahim 13, Timothy Kubal 2, Andrew D Leavitt 14, Ming Lim 15, Janelle Mann 16, Simon Mantha 17, Colleen Morton 18, Alex Nester 19, Andrew O'Brien 20, Thomas L Ortel 21, Alexander Pine 22, Allyson Pishko 23, Mona Ranade 24, Amirali Salmasi 25, Jordan Schaefer 26, Eliot Williams 27, Geoffrey Wool 28, Theodore Wun 29, Sarah Montgomery 30, Jamie Nguyen 30, Deborah Freedman-Cass 30, Bailee Sliker 30

Affiliations

Practice Guideline

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Michael B Streiff et al. J Natl Compr Canc Netw. 2024 Sep.

Abstract

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources